We are pleased to announce that PlumeStars has received the certification “Seal of Excellence” delivered by the European Commission, as the institution managing Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020.
Read more “Hyalcis’s SEAL OF EXCELLENCE certificate by the European Commission”
We are pleased to announce that the Controlled Release Society (CRS) has announced the election of Paolo Colombo, Pharm. D., Ph.D., CEO of PlumeStars, Emeritus Professor, Department of Food and Drug, University of Parma, Italy to its College of Fellows.
Read more “PAOLO COLOMBO ELECTED INTO CONTROLLED RELEASE SOCIETY (CRS) COLLEGE OF FELLOWS”
We are pleased to announce that The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Paolo Colombo, Pharm. D., Ph.D., CEO of PlumeStars, Emeritus Professor, Department of Food and Drug, University of Parma, Italy to its College of Fellows.
Read more “Paolo Colombo Inducted into Medical and Biological Engineering Institute (AIMBE)”
Paolo Colombo, Emeritus of the University of Parma and CEO of PlumeStars, has been named among the top 60 industrial leaders in The Medicine Maker’s 2020 Power List 2020.
On 9th and 10 th December 2019, at the Department of Food and Drug of the University of Parma, the two days course “Quality by Design in Pharmaceutical Development. Theory and case studies”, will take place.
From 3rd to 6th of November, PlumStars will participate at AAPS 2019 AAPS, an annual Conference of the American Association of Pharmaceutical Scientists that will be held at Henry B. González Convention Center, San Antonio, TX, USA.
There will be pitching, demonstrations and great presentations, with take-aways for both investors and innovation driven organizations.
Prof. Paolo Colombo (PlumeStars CEO) will present two different speeches:
The first speech concerns Hyalcis exploits nanotechnology and advanced material research results to bring to market an innovative medical treatment of mesothelioma. The studies until now conducted revealed an interaction between the polymer hyaluronic acid and cisplatin that gave rise to a drug-polymer complex, lymphatically absorbed and blood distributed.
The uptake by pharmaceutical industry of the hyaluronic- cisplatin film technology studied by PlumeStars will assign a more effective cure against recurrences of this rare and very aggressive form of cancer that is difficult to diagnose and highly resistant to anticancer drugs.
Dr. Eride Quarta (PharmD; PhD Student, PlumeStars Research Leader) will present:
AAPS PharmSci 360 combines all the energy of a large scientific conference with the intimacy of a niche meeting.
Five robust tracks covering all aspects of the pharmaceutical sciences, hundreds of exhibitors with dozens of additional learning opportunities, thousands of scientific posters featuring the latest, most innovative research in the field.
On 9 October 2019 PlumeSTARS will actively participate at the fourth edition of the Italian Innovation Day that will be held in Tokyo, together with other promising start-ups on the international scene.
There will be pitching, demonstrations and great presentations, with take-aways for both investors and innovation driven organizations.
Keynote speaker will be the startup journalist Emil Abirascid and supporter of the Italian Innovation Day since the first edition. He will tell us about the latest trends in the Italian startup and venture capital ecosystem, analyse current situation and identify cooperation and investment opportunities for Japanese corporations.
Masaru Ikeda, supporter of the event since 2017, will be Master of Ceremony together with Emil Abirascid. Startup journalist and experienced moderator, he will treat us with insightful comments and valuable questions to the speakers.
An exciting occasion to know about the Italian startup ecosystem and the investment and business opportunities it offers.
Italian startups pitching their ideas, business experts introducing the Italian startup ecosystem and VC industry, guest speakers giving precious insights.
For more information:
Prof. Paolo Colombo, CEO of PlumeSTARS and Dr. Eride Quarta, Research Scientist of PlumeSTARS, attended the 5th International TB Meeting “Inhaled therapies for tuberculosis and other infectious diseases” in Groningen (The Netherlands) from 25 to 27 August 2019.
Prof. Paolo Colombo, as chairman, opened the First Session on formulations and devices, saying that Integrating the tuberculosis systemic drug administration with targeted loco-regional treatment improves the therapy effectiveness. The congress proposal in this direction was to introduce the administration of anti-bacterial drugs by inhalation as an adjunct to systemic therapy. This strategy allows a direct attack to the Mycobacterium tuberculosis, i.e., the disease responsible.
Pulmonary drug products, in particular the most technologically advanced dry powders inhalers, imply a demanding pharma-tech development, since numerous variables for controlling the deposition of drug particles are involved. Bronchial or alveolar regions are the targets of TB disease.
The powders for inhalation are essentially formulated by crushing drug particles by milling or by constructing ex novo microparticulate shapes. In general, in infective lung diseases, the products present a high amount of powder to inhale for dose administration. In addition, in TB, more than one drug has to be delivered at same time. This forces the device technologies for metering, aerosolization and deposition to be strongly innovative.
In summary, formulation and device for anti-TB dry powder inhalation products are not simple combination products. Their sophistication is essential to facing the interaction among product, patient and microbial target. Local concentration of antibiotics, retention time and compliance with daily dosing could also suggest compounding of prolonged release formulations, using colloidal particles and controlling dissolution rate using compatible safe polymers. Therefore, novel inhaled antibiotic formulations, such as dry powder for inhalation, are promising as problem solving drug composition.
Finally, also Dr. Eride Quarta,research scientist of PlumeStars and PhD student of Department of Food& Drug at Parma University, presented the research contribution“Microparticles embedding streptomycin sulfate and isoniazid albumin co-nanoparticles for dry powder inhalers”.
PlumeSTARS is proud to announce that it has been selected among the 8 companies that will be able to access the “Business Match in Silicon Valley” and the related preparation and mentoring activities.
Since 2015, the Emilia-Romagna Region has been present in Silicon Valley through the AR-TER Consortium Company, which manages regional internationalization projects towards the Silicon Valley and the permanent facility in San Francisco. Since 2017, the Emilia-Romagna Region has expanded its activities to involve only the startups, but the whole regional innovative ecosystem, starting from the most innovative companies.
The program includes various operational phases: scientific training – to be carried out both in Emilia Romagna and in Silicon Valley – up to moments of pitching, investor events and B2B meetings with possible partners.
The mission in Silicon Valley will be held from 18 to 22 November 2019 and foresees the realization of meetings personalized and group meetings between a representative of up to 8 companies selected and potential partners interested in Silicon Valley.
The Silicon Valley is the nerve center of the global startup and innovation ecosystem, where the majority of investment collection opportunities are gathered, strategic partners and global business contacts are sought.
Since 2015, the Emilia-Romagna Region has been present in Silicon Valley through the ASTER Consortium Company, which manages regional internationalization projects towards Silicon Valley and the permanent facility in San Francisco. Since 2017, the Emilia-Romagna Region has expanded its activities to involve not only the startups, but the whole regional innovative ecosystem, starting from the most innovative companies.
PlumeSTARS was chosen among the 16 companies on the list that have passed the pre-assessment and are therefore invited to participate in the boot camp on 25, 26 and 27 June 2019 in Bologna.
The Business Match program and the related boot camp are managed by ART-ER thanks to funds from the Emilia-Romagna Region. Topics of the Emilia-Romagna actions in Silicon Valley, with the collaboration of the USMAC partner – US Market Access Center. The co-CEOs of the Company, Alfredo Coppola and Chris Burry, will be in Bologna to hold the boot camp.
The boot camp is an intensive training on how to do business with Silicon Valley, but also an evaluation step of the Call: at the end of the boot camp, in fact, the 8 companies that will access the Business Match service program in Silicon Valley itself.
